In 1999, at the University of Wisconsin, Dr. Paul Harari’s group identified that targeting the epidermal growth factor receptor (EGFR) with the monoclonal antibody cetuximab (C225) resulted in reduced proliferation, cell cycle arrest, enhanced apoptosis, and improved radiosensitivity of HNSCC cells in vitro [6]. Here, EGFR is linked to head and neck squamous cell carcinoma.